Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
Total raised: $78M
Investors 1
| Date | Name | Website |
| 30.05.2025 | Cambridge ... | cic.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.06.2026 | Seed | $47M | Eli Lilly ... |
| 06.03.2025 | Seed | $31M | - |
Mentions in press and media 17
| Date | Title | Description |
| 23.06.2026 | TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio | Cambridge, UK, 23 June 2026: TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today ann... |
| 23.06.2026 | Trimtech Therapeutics Raises Additional $14M in Seed Funding | Trimtech Therapeutics, a Cambridge, UK-based biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, raised additional $14M in Seed funding. Back... |
| 24.02.2026 | BioMed Realty and Babraham Research Campus Ltd Complete Lease-Up of Newest Building at Babraham Research Campus, with TRIMTECH Therapeutics and Tagomics | BioMed Realty, the largest private operator of real estate for the life science and technology industries, today announced the completion of the lease-up of the newest laboratory building at Babraham Research Campus, following new leases wi... |
| 17.02.2026 | Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines | Aerska, an Irish biotech firm, secured a $39 million Series A funding round. This significant investment will propel its proprietary brain shuttle technology. The platform targets challenging neurological diseases. It delivers RNA medicines... |
| 10.02.2026 | Irish BioTech startup Aerska raises €32 million to “enable our loved ones to live longer” | Dublin’s Aerska, a BioTech company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a €32 million ($39 million) Series A financing to improve delivery of RNAi interference (RNAi) therape... |
| 20.01.2026 | German BioTech Exciva lands €51 million to advance Alzheimer’s drug testing in patients | Heidelberg-based Exciva, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59 million) Series B round. Gimv and EQT Life Scien... |
| 02.12.2025 | TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board | Cambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment ... |
| 12.11.2025 | The UK’s Scripta Therapeutics raises over €10 million to “flip the script” on drug discovery | Oxford BioTech startup Scripta Therapeutics emerges from stealth today by announcing a €10.3 million ($12 million) Seed round to upend conventional approaches to drug discovery. The round is led jointly by Oxford Science Enterprises (OSE) a... |
| 11.04.2025 | Italy's Tech Renaissance: A Surge Amid Global Challenges | Italy is on the rise. The tech sector is thriving, defying global economic headwinds. In the first quarter of 2025, Italy raised over $315 million. This figure mirrors last year’s performance, signaling resilience. The enterprise value of t... |
| 09.04.2025 | Europe’s biggest seed rounds of Q1 2025: Top tech startups to watch | The Tech.eu Q1 2025 Report reveals that European tech companies raised €18.4 billion across 912 deals during the first quarter of 2025. Approximately 12.7 per cent of these companies successfully closed seed rounds, amounting to nearly half... |
Show more